CatalystMarker
Sign in
← board

ALNY

Alnylam Pharmaceuticalsdistress 1/10 · well-funded / low risk
$266.150%today-46% from 52w high
alnylam.com2,500 employeesFounded 2002Cambridge, MABiotechnology
Lead: Hypertension · est. market ~$25B (approx, global)
Revenue
$3714M
Liquidity
$1657M
Runway
—
Shares 1y
+1%

Price & events

-28.1% over 6M
$266$318$370Jan 26Apr 26Jul 265.9Mrating: B of A Securities: Buy (2026-07-14)rating: Truist Securities: Buy (2026-07-13)rating: HC Wainwright & Co.: Buy (2026-07-13)rating: Morgan Stanley: Equal-Weight (2026-07-10)rating: HC Wainwright & Co.: Buy (2026-06-29)rating: HC Wainwright & Co.: Buy (2026-06-04)rating: Citigroup: Buy (2026-05-19)rating: HC Wainwright & Co.: Buy (2026-05-05)
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-6.0%
1W
-7.6%
1M
-15.2%
3M
-25.7%
6M
-18.3%
1Y
+13.6%
2Y
+45.9%
5Y
+107.8%
All

Overview

Market Cap
$35.30B
Volume
42.39K
52 Week Range
$266 – $491
Total Shares
132.62M
Float Shares
132.94M
Short %
5.79%
% Held by Insiders
0.18%
% Held by Institutions
102.02%
RVOL
0.03x
Beta
0.27

Pipeline stages · 6 programs

ALN-AGT01 RVR, Zilebesiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-27
Nucresiran, Vutrisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12-27
Vutrisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03-31
Mivelsiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-05-18
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-05-28
Zilebesiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-09-30

Pipeline · 14 trials · 13 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-04-27
Estimated 50%
readout ~2027-06-11
Phase 1/2ALN-2232, TirzepatideObesity—recruiting
2027-05-28
Estimated 50%
readout ~2027-07-12
Phase 2ALN-4324Type 2 Diabetes Mellitus (T2DM)—recruiting
2027-06-30
Estimated 50%
readout ~2027-08-14
Phase 2ALN-6400Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)—not yet recruiting
2027-08-09
Estimated 50%
readout ~2027-09-23
Phase 2ALN-APPCerebral Amyloid Angiopathy—recruiting
2027-08-31
Estimated 50%
readout ~2027-10-15
Phase 1/2ALN-4324Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)—recruiting
Show all 14 trials · 9 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-09-30
Estimated 50%
readout ~2027-10-30
Phase 1ALN-BCAT, PembrolizumabAdvanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma—recruiting
2027-12-27
Estimated 50%
readout ~2028-03-11
Phase 3Nucresiran, VutrisiranHereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN—recruiting
2028-01-05
Estimated 50%
readout ~2028-02-19
Phase 1/2ALN-6400Hereditary Hemorrhagic Telangiectasia—recruiting
2028-03-31
Estimated 50%
readout ~2028-06-14
Phase 3VutrisiranTransthyretin Amyloidosis (ATTR) With Cardiomyopathy—enrolling by invitation
2028-04-01
Estimated 50%
readout ~2028-05-16
Phase 2ALN-AGT01 RVR, ZilebesiranHypertension—recruiting
2030-05-18
Estimated 50%
readout ~2030-07-02
Phase 2MivelsiranDown Syndrome-Associated Alzheimer's Disease (DS-AD)—not yet recruiting
2030-05-28
Estimated 50%
readout ~2030-08-11
Phase 3Nucresiran, Sterile Normal Saline (0.9% NaCl)Transthyretin Amyloidosis With Cardiomyopathy—recruiting
2030-09-30
Estimated 50%
readout ~2030-12-14
Phase 3ZilebesiranHigh Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk—recruiting
2025-09-08
Phase 1ALN-AGT01 RVRHealthy Volunteers42completed

Catalyst news & presentations · 1

Approved drugs (4)

  • AMVUTTRAVUTRISIRAN SODIUM2022 · Prescription
  • OXLUMOLUMASIRAN SODIUM2020 · Prescription
  • GIVLAARIGIVOSIRAN SODIUM2019 · Prescription
  • ONPATTROPATISIRAN SODIUM2018 · Prescription

Capital structure — dilution & financing

Shares out: 132,623,144 · 0 offerings/1y · 1 PIPEs
  • 2025-10-038-Kmaterial_agreement
  • 2025-09-128-Kprivate_placement
  • 2024-11-12SC 13G/Astrategic_stake
  • 2024-11-08SC 13G/Astrategic_stake
  • 2024-08-12SC 13G/Astrategic_stake
  • 2024-07-05SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $435 (+63% upside) · 23 analysts
  • 2026-07-14B of A SecuritiesBuy
  • 2026-07-13Truist SecuritiesBuy
  • 2026-07-13HC Wainwright & Co.Buy
  • 2026-07-10Morgan StanleyEqual-Weight
  • 2026-06-29HC Wainwright & Co.Buy
  • 2026-06-04HC Wainwright & Co.Buy

Competitors — Hypertension

  • LLYELI LILLY & Co$1094.4B · D3
  • MRKMerck & Co., Inc.$318.8B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • INSMINSMED Inc$22.9B · D2
  • MLYSMineralys Therapeutics, Inc.$2.1B · D6
  • SGPSpyGlass Pharma, Inc.$682M · D2
  • TECXTectonic Therapeutic, Inc.$589M · D0
  • IKTInhibikase Therapeutics, Inc.$289M · D4
  • GALTGALECTIN THERAPEUTICS INC$231M · D5
  • GOSSGossamer Bio, Inc.$33M · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.